查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球基础胰岛素（长效胰岛素）市场 - 2023-2030年
市场调查报告书
商品编码
1290383

全球基础胰岛素（长效胰岛素）市场 - 2023-2030年

Global Basal Insulin (Long-Acting Insulin) Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球基础胰岛素（长效胰岛素）市场在2022年达到了2.348亿美元，预计到2030年将会出现有利可图的增长，达到3.316亿美元。全球基础胰岛素（长效胰岛素）市场在预测期内（2023-2030）预计将呈现4.5%的复合增长率。

糖尿病发病率的上升，有前途的还款准则，以及产品引进、产品授权、合并、投资、合作和扩张等市场发展，正在推动全球基础胰岛素（长效胰岛素）市场的增长。该市场的主要参与者包括Novo Nordisk AS、Sanofi Aventis和Biocon等。

市场动态

糖尿病病例的增加推动了基础胰岛素（长效胰岛素）市场的增长。

糖尿病病例的增加正在推动全球基础胰岛素（长效胰岛素）市场的增长。例如，根据就医基金会的数据，糖尿病在全球范围内迅速增长，每年诱发670万人死亡。获得胰岛素是一个越来越关键的多国健康重要性。预计到2030年，全球糖尿病患者人数将超过6.43亿，到2045年将达到7.83亿，在中低收入国家增长最快，这些国家在获得胰岛素方面存在着明显的不平等。

各种患者援助计划的存在为市场增长创造了有利可图的机会。

各种患者援助计划的存在为市场提供了未来几年的增长机会。例如，礼来公司的关爱计划、诺和诺德公司的患者援助计划（PAP）NovoCare、Insulins ValYOU储蓄计划、直接购买计划和Insulin Glargine Follow-On Biologic等都为胰岛素的购买提供了低成本或还款。

严格的监管机构阻碍了市场的发展。

严格的监管机构控制着胰岛素产品的开发和商业化，这使得全球基础胰岛素（长效胰岛素）市场的增长缓慢。例如，控制胰岛素开发和商业化的主要监管机构包括FDA和EMA。上述因素限制了基础胰岛素（长效胰岛素）市场的增长。

COVID-19影响分析

由于COVID-19大流行和世界上许多国家的封锁，所有行业的公司的财务健康都受到了影响。因此，在COVID-19公共卫生紧急情况期间，美国食品和药物管理局（FDA）发布了指导方针，其中包括帮助赞助商和研究人员的一般注意事项，确保试验参与者的安全，坚持良好的临床实践（GCP），并尽量减少试验完整性的风险。

俄乌战争影响分析

俄罗斯-乌克兰冲突估计会对全球基础胰岛素（长效胰岛素）市场产生适度的影响，因为该地区流行率低且没有关键的市场参与者。然而，乌克兰的诊所一直忍受着俄罗斯军队的入侵，死亡人数不断增加，医疗储备有限。所有种类的药品都存在缺陷，但胰岛素储备的限制导致与未受控制的糖尿病相关的疾病上升。另外，原材料进出口的影响预计在预测期内对全球基础胰岛素（长效胰岛素）市场增长的影响很小。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按产品类型分類的摘要
  • 按应用分类的摘要
  • 按分销渠道分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 市场的发展
      • 日益普遍的情况
    • 限制因素
      • 副作用
    • 机会
      • 报销
    • 影响分析

第五章：行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按产品类型

  • 兰特斯
  • 勒维米
  • 妥吉奥
  • 特雷西巴
  • 巴沙格拉
  • 胰岛素Glargine生物仿制药

第8章：按应用分类

  • 1型糖尿病
  • 2型糖尿病

第九章：按分销渠道分类

  • 医院药房
  • 零售药店
  • 网上药店

第十章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
      • 亚太其他地区
  • 中东和非洲
    • 主要地区的动态

第11章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十二章 ：公司简介

  • Novo Nordisk AS
    • 公司概述
    • 产品组合和说明
    • 财务概况
    • 主要发展情况
  • Sanofi Aventis
  • Biocon
  • Julphar
  • Pfizer
  • Ganli Pharmaceutical Co., Ltd
  • Mylan
  • Wockhardt
  • Eli Lily

第十三章 ：附录

简介目录
Product Code: PH4712

Market Overview

The Global Basal Insulin (Long-Acting Insulin) Market reached US$ 234.8 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 331.6 million by 2030. The global basal insulin (long-acting insulin) market is expected to exhibit a CAGR of 4.5% during the forecast period (2023-2030).

The rising incidence of diabetes, promising repayment guidelines, and market developments like product introduction, product authorizations, consolidations, investments, partnerships, and expansion among others are boosting the global basal insulin (long-acting insulin) market growth. The key players in this market include Novo Nordisk AS, Sanofi Aventis, and Biocon among others.

Market Dynamics

An Increase In Diabetes Cases Drives The Growth Of The Basal Insulin (Long-Acting Insulin) Market.

The growing cases of diabetes are driving the global basal insulin (long-acting insulin) market growth. For instance, according to the Access to Medicine Foundation, diabetes increases rapidly globally, inducing 6.7 million deaths annually. Access to insulin is an increasingly critical multinational health importance. The number of individuals with diabetes globally is anticipated to surpass 643 million by 2030, and 783 million by 2045 rising most quickly in low- and middle-income countries (LMICs), where there is stark inequity in access to insulin.

Presence Of Various Patient Assistance Programs Creates Lucrative Opportunities For Market Growth.

The presence of various patient assistance programs presents the market with prospective growth opportunities in the upcoming years. For instance, Lilly Cares Program, Novo Nordisk Patient Assistance Program (PAP) NovoCare, Insulins ValYOU Savings Program, Direct Purchase Program, and Insulin Glargine Follow-On Biologic among others provide low-cost or repayment on insulin purchases.

Stringent Regulatory Authorities Hamper the Growth of the Market.

The presence of stringent regulatory authorities controlling the development and commercialization of insulin products slows the global basal insulin (long-acting insulin) market growth. For instance, the major regulatory authorities controlling the development and commercialization of insulin include the FDA and EMA. Above mentioned factors are limiting the basal insulin (long-acting insulin) market growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global basal insulin (long-acting insulin) market, owing to the low prevalence and absence of key market players in this region. However, persisting to countenance invasions from Russian armies, Ukrainian clinics are pushed by rising numbers of deaths and limited medical reserves. There are deficiencies across all kinds of medicine, but restricted access to insulin reserves has guided to an uptick in disorders associated with uncontrolled diabetes. Also, the influence of the import and export of raw materials are anticipated to have little influence over the global basal insulin (long-acting insulin) market growth over the forecast period.

Segment Analysis

The global basal insulin (long-acting insulin) market is segmented based on product type, application, distribution channels and region.

Hospital Pharmacies Segment Accounts for 40% of the Market Share.

Owing to the increasing number of hospitals, the availability of investigational developments, and ease of reimbursement, the hospital pharmacies segment is estimated to hold 42.3% of the global market share. For instance, according to the Republic of Estonia Agency of Medicines, in 2022, the total earning of hospital pharmacies was 137 million euros, with an upsurge of 3% in total compared to previous results.

Geographical Analysis

Europe is Estimated to Hold 28.6% of the Market Share Owing to the Growing Diabetes Prevalence in this Region

Owing to the growing prevalence of diabetes in Europe, the region is estimated to hold the second-largest share accounting for 28.6% of the global basal insulin (long-acting insulin) market. For instance, according to the World Health Organization, there are approximately 60 million individuals with diabetes in the European Region, or roughly 10.3% of males and 9.6% of females aged 25 years and above. The preponderance of diabetes is rising among all ages in the European Region, principally because of additions in overweight and obesity, harmful diet, and physical laziness.

Competitive Landscape

The major global players in the basal insulin (long-acting insulin) market include: Novo Nordisk AS, Sanofi Aventis, Biocon, Julphar, Pfizer, Ganli Pharmaceutical Co., Ltd, Mylan, Wockhardt, and Eli Lily among others.

Why Purchase the Report?

  • To visualize the global basal insulin (long-acting insulin) market segmentation based on product type, application, distribution channels and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of basal insulin (long-acting insulin) market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global basal insulin (long-acting insulin) market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Distribution Channels
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Market Developments
      • 4.1.1.2. Growing Prevalence
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effect
    • 4.1.3. Opportunity
      • 4.1.3.1. Reimbursement
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Lantus *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Levemir
  • 7.4. Toujeo
  • 7.5. Tresiba
  • 7.6. Basaglar
  • 7.7. Insulin Glargine Biosimilars

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Type 1 Diabetes *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Type 2 Diabetes

9. By Distribution Channels

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 9.1.2. Market Attractiveness Index, By Distribution Channels
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Novo Nordisk AS*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Sanofi Aventis
  • 12.3. Biocon
  • 12.4. Julphar
  • 12.5. Pfizer
  • 12.6. Ganli Pharmaceutical Co., Ltd
  • 12.7. Mylan
  • 12.8. Wockhardt
  • 12.9. Eli Lily

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us